natgillin/translations-raw huggingface dataset:
<Can be used during pregnancy.>
<Lahko se uporablja v obdobju brejosti.>
<Duration of immunity: {x years}>
<Trajanje imunosti: {x let}>
<Do not use within {X} weeks of the start of the laying period.>
<Ne uporabite v obdobju {X} tednov pred začetkom obdobja nesnosti.>
<Medicines should not be disposed of via wastewater or <household waste>.>
<Ne odvrzite zdravila v odpadno vodo ali <med gospodinjske odpadke>.>
<Appropriate veterinary and husbandry measures should be taken to avoid spread of the vaccine strain to susceptible species.>
<Potrebni so ustrezni veterinarski in živinorejski ukrepi, da bi preprečili širitev vakcinalnega seva na dovzetne živalske vrste.>
<Vaccinate healthy animals only.>
<Cepite samo zdrave živali.>
<The import, possession, sale, supply and/or use of this veterinary medicinal product may be prohibited in a Member State on the whole or part of its territory, see package leaflet for further information.>
<Uvoz/vnos, posedovanje, prodaja, oskrba in/ali uporaba tega zdravila je lahko v državi članici prepovedana na njenem celotnem ozemlju ali delu ozemlja; za nadaljnje informacije glej navodilo za uporabo.>
<Date of last renewal:> <{DD/MM/YYYY}> <{DD month YYYY}.>
<Datum zadnjega podaljšanja dovoljenja za promet:> <{DD/MM/LLLL}> <{DD mesec LLLL}.>
<Do not use in cases of hypersensitivity to the active substance(s)<, to the adjuvant(s)> or to any of the excipient(s).>
<Ne uporabite v primerih preobčutljivosti na učinkovino(e) <, na dodatek(dodatke)> ali na katero koli pomožno snov.>
<Do not use {name of product} if you notice {description of the visible signs of deterioration}.>
<Ne uporabite {ime zdravila}, če opazite {opis vidnih znakov kvarjenja}.>
<Do not use in <birds in lay><breeding birds> <and within 4 weeks before the start of the laying period>.>
<Ne uporabite <pri pticah v obdobju nesnosti> <vzrejnih pticah> <in 4 tedne pred začetkom obdobja nesnosti.>
{(Invented) name of veterinary medicinal product <strength> pharmaceutical form}
{(Izmišljeno) ime zdravila za uporabo v veterinarski medicini <jakost> farmacevtska oblika}
DescriptionDue date>>
OpisDo datuma>
<In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.>
<Zaradi pomanjkanja študij kompatibilnosti tega zdravila ne smemo mešati z drugimi zdravili za uporabo v veterinarski medicini.>
<Do not use in pregnant animals which are intended to produce milk for human consumption within {X} months of expected parturition.>
<Ne uporabite pri brejih živalih, katerih mleko je namenjeno prehrani ljudi, v obdobju {X} mesecev pred pričakovanim porodom.>
· CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
<People with known hypersensitivity to {INN} should <avoid contact with the veterinary medicinal product.><administer the veterinary medicinal product with caution.>>
<Osebe z znano preobčutljivostjo na {INN} naj <se izogibajo stiku z zdravilom.> <zdravilo dajejo previdno.>>
<Do not mix with any other veterinary medicinal product<, except <solvent or other component> <recommended><supplied> <for use with the veterinary medicinal product>.>
<Ne mešajte z nobenim drugim zdravilomza uporabo v veterinarski medicini <, razen z vehiklom ali drugo komponento> <, ki je priporočena> <, ki je priložena> < za uporabo s tem zdravilom>.>
<<Meat and offal><Eggs><Milk> <Honey>: {X} <days><hours>.>
<<Meso in organi> <Mleko> <Jajca> <Med>: {X} <ur><dni>.>
<{Species} and unvaccinated {species} in contact with vaccinated {species} may react to the vaccine strain, presenting clinical signs such as ….>
<{Živalske vrste} in necepljene {živalske vrste} lahko v stiku s cepljenimi {živalskimi vrstami} reagirajo na vakcinalni sev in pri tem kažejo klinične znake kot npr…>
<The <vaccine><immunological veterinary medicinal product><veterinary medicinal product> should not be used if {description of the visible signs of deterioration}.>
<Cepiva> <imunološkega zdravila> <zdravila> ne smemo uporabiti če {opis vidnih znakov kvarjenja}.>
<In case of accidental <self-administration><self-injection><ingestion><spillage onto skin>, seek medical advice immediately and show the package leaflet or the label to the physician.>
<V primeru nenamerne(ga) <samo-aplikacije> <samo-injiciranja> <zaužitja> <razlitja po koži> se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali ovojnino.>
<Do not use (during the whole or part of the pregnancy).>
<Ne uporabite (v celotnem ali delnem obdobju brejosti).>
<The use is not recommended (during the whole or part of the pregnancy).>
<Uporaba ni priporočljiva (v celotnem ali delnem obdobju brejosti).>
<Store in a refrigerator (2 (C - 8 (C).>
<Shranjujte v hladilniku (2 (C - 8 (C).>
<Disposal: read package leaflet.>
<Odstranjevanje: preberite navodilo za uporabo.>
<Environmental properties>
<Okoljski podatki>
<The MAH shall complete, within the stated timeframe, the following measures:
<Imetnik dovoljenja za promet z zdravilom mora v spodaj navedenem časovnem okviru izvesti naslednje ukrepe:
Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.>
Potreben je strokoven, TAKOJŠEN, kirurški poseg ter morda tudi takojšnja incizija in izpiranje injiciranega mesta, zlasti če so prizadete tudi kite ali mehka tkiva prsta.>
The Committee for Medicinal Products for Veterinary Use has recommended the inclusion of {name of the active substance(s)} in {name of the product} in table 1 (Allowed substances) of the annex to Commission Regulation (EU) No 37/2010 as follows:
Odbor za zdravila za uporabo v veterinarski medicini je priporočil vključitev {ime učinkovine} v {ime zdravila} v tabelo 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št. 37/2010:
<5.2 Pharmacokinetic particulars>
<5.2 Farmakokinetični podatki>
<Once <broached><opened><diluted><reconstituted> <use by…> <use within…> <use immediately>.>
<Načeto> <odprto> <razredčeno> <rekonstituirano> zdravilo uporabite do…> <uporabite v…> <uporabite takoj>.>
<Not authorised for use in animals producing milk for human consumption.>
<Ni dovoljena uporaba pri živalih, katerih mleko je namenjeno prehrani ljudi.>
<The <veterinary medicinal product><vaccine><immunological veterinary medicinal product> should be given at different sites.>
<To <zdravilo> <cepivo> < imunološko zdravilo> se daje na različna mesta.>
<The use is not recommended during <pregnancy><lactation>.>
<Uporaba ni priporočljiva v obdobju <brejosti> <laktacije>.>
During this time, the contact of immunosuppressed and unvaccinated {species} with vaccinated {species} should be avoided.>
V tem času se je treba izogibati stikom imunsko oslabljenih {živalskih vrst} in necepljenih {živalskih vrst} s cepljenimi {živalskimi vrstami}.>
<Date of first authorisation:> <{DD/MM/YYYY}><{DD month YYYY}.>
<Datum pridobitve dovoljenja za promet:> <{DD/MM/LLLL}> <{DD mesec LLLL}.>
<The veterinary medicinal product should not be administered by pregnant women.>
<Tega zdravila naj ne dajejo nosečnice.>
<Store in a refrigerator.>
<Shranjujte v hladilniku.>
<<Accidental administration> <Contact with the mucosa> is dangerous.>
<Nenamerna aplikacija> <Stik s sluznico> je nevaren(no).>
<5.1 Pharmacodynamic properties>
<5.1 Farmakodinamične lastnosti>
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION>
DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM>
<Laboratory studies in {species} have shown evidence of <teratogenic>, <foetotoxic>, <maternotoxic> effects.>
<Z laboratorijskimi študijami {na živalskih vrstah} so bili dokazani <teratogeni>, <fetotoksični> <učinki>, <toksični učinki na mater.>>
<This veterinary medicinal product does not require any special storage conditions.>
< Za shranjevanje zdravila niso potrebna posebna navodila.>
<Shelf life after first opening the container: ….>
<Rok uporabnosti po prvem odpiranju vsebnika: ….>
<Store and transport refrigerated (2 (C - 8 (C).>*
<Shranjujte in prevažajte v hladilniku (2 (C - 8 (C).>*
<Laboratory studies in {species} have not produced any evidence of <teratogenic>, <foetotoxic>, <maternotoxic> effects.>
< Z laboratorijskimi študijami {na živalskih vrstah} niso bili dokazani <teratogeni>, <fetotoksični> <učinki>, <toksični učinki na mater.>>
<Read the package leaflet before use.>
<Pred uporabo preberite navodilo za uporabo.>
The active substance
 in {name of the product} <is><are> <an> allowed substance
 as described in table 1 of the annex to Commission Regulation (EU) No 37/2010:
<Učinkovina> <Učinkovine> v {ime zdravila}<je dovoljena učinkovina><so dovoljene učinkovine>, kot <je navedena> <so navedene> v tabeli 1(dovoljene snovi) priloge Uredbe Komisije (EU) št. 37/2010:
Do not use this veterinary medicinal product after the expiry date which is stated on the <label><carton><bottle><...> <after {abbreviation used for expiry date}>.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na <ovojnini > <škatli> <steklenici> <...> po {kratica, ki se uporablja za datum izteka roka uporabnosti}.> <Rok uporabnosti zdravila se nanaša na zadnji dan v navedenem mesecu.>
<Shelf life after incorporation into meal or pelleted feed: >
<Rok uporabnosti po vključitvi v obrok ali peletirano hrano: >
<Safety> <and> <efficacy> data are available which demonstrate that this <vaccine><immunological veterinary medicinal product> can be administered at least {X} <days><weeks> <before><after> the administration of {description of tested product(s).
<Podatki o varnosti <in> <učinkovitosti> so pokazali, da je to <cepivo> <imunološko zdravilo> varno dati vsaj {X} <dni> <tednov> <pred> <po> dajanju {opis testiranega(ih) proizvoda(ov)}.>
<The safety of the veterinary medicinal product has not been established during <pregnancy><lactation><lay>.>
<Varnost zdravila v obdobju <brejosti> <laktacije> <nesnosti > ni bila ugotovljena.
<Store and transport frozen.>**
<Shranjujte in prevažajte zamrznjeno.>**
<Store and transport frozen {temperature range}.>**
<Shranjujte in prevažajte zamrznjeno {temperaturni interval}.>**
<Name and address of the manufacturer
 of the biological active substance

<Ime in naslov proizvajalca(proizvajalcev) biološke (bioloških)učinkovine (učinkovin)
<The excipients listed in section 6.1 of the SPC are <either> <allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required> <or> <considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product>.>
<Pomožne snovi, navedene v poglavju 6.1 SPC <so bodisi> < dovoljenje snovi, za katere tabela 1 priloge Uredbe Komisije (EU) št. 37/2010 določa, da MRL ni potreben> <ali pa> <ne spadajo v področje uporabe Uredbe (ES) št. 470/2009, kadar so uporabljene tako kot v tem zdravilu za uporabo v veterinarski medicini>.>
<Shelf life of the veterinary medicinal product as packaged for sale: >
<Rok uporabnosti zdravila v pakiranju za prodajo: >
<Onset of immunity: {x weeks}>
<Nastop imunosti: {x tednov}>
<Zero days.>
<Nič dni.>
<Shelf life after <dilution><reconstitution> according to directions: >
<Rok uporabnosti po <razredčenju> <rekonstituciji> v skladu z navodili: >
A. <MANUFACTURER<S> OF THE BIOLOGICAL ACTIVE SUBSTANCE<S> AND> MANUFACTURER<S> RESPONSIBLE FOR BATCH RELEASE
A. <PROIZVAJALEC (PROIZVAJALCI) BIOLOŠKE (BIOLOŠKIH) UČINKOVINE (UČINKOVIN) IN> PROIZVAJALEC (PROIZVAJALCI) ZDRAVILA ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ
<Safety> <and> <efficacy> data are available which demonstrate that this <vaccine><immunological veterinary medicinal product> can be administered on the same day but not mixed with {description of tested product(s).
<Podatki o <varnosti> <in> <učinkovitosti> so pokazali, da je to <cepivo> <imunološko zdravilo> varno dati na isti dan vendar ne zmešano z {opis testiranega(ih) proizvoda(ov)}.>
Name and address of the manufacturer
 responsible for batch release
Ime in naslov proizvajalca(proizvajalcev) zdravila, odgovornega (odgovornih) za sproščanje serij
Marketing authorisation holder <and manufacturer responsible for batch release>:
<Imetnik dovoljenja za promet z zdravilom <in proizvajalec odgovoren za sproščanje serij>:
<Safety <and> <efficacy> data are available which demonstrate that this <vaccine><immunological veterinary medicinal product> can be mixed and administered with {description of tested product(s).
<Podatki o varnosti <in> <učinkovitosti> so pokazali, da se to <cepivo> <imunološko zdravilo> lahko meša in daje z {opis testiranega(ih) proizvoda(ov).
<Shelf life after <dilution><reconstitution> according to directions: ….>
<Rok uporabnosti po <razredčenju> <ali> <rekonstituciji> v skladu z navodili: ….>
<The excipients, listed in section 6.1 of the SPC are <either> <allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required> <or> <considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product>.>
SPC <so bodisi> < dovoljenje snovi, za katere tabela 1 priloge Uredbe Komisije (EU) št. 37/2010 določa, da MRL ni potreben> <ali pa> <ne spadajo v področje uporabe Uredbe (ES) št. 470/2009, kadar so uporabljene tako kot v tem zdravilu za uporabo v veterinarski medicini>.>
<To be supplied only on veterinary prescription.>
<Zdravilo lahko daje samo veterinar.>
<Shelf life after first opening the immediate packaging: >
<Rok uporabnosti po prvem odpiranju stične ovojnine: >
<Store in a freezer.>
<Shranjujte v zamrzovalniku.>
<Personal protective equipment consisting of {specify} should be worn when handling the veterinary medicinal product.>
<Pri ravnanju z zdravilom nosite osebno zaščitno opremo, ki sestoji iz {opredelite}.>
<Laying birds:>
<Ptice v obdobju nesnosti:>
<The vaccine strain can spread to {species}.Special precautions should be taken to avoid spreading of the vaccine strain to {species}.>
Potrebni so posebni previdnostni ukrepi, da bi se izognili širjenju vakcinalnega seva na {živalske vrste}.>
<Pregnancy:> <and lactation:>
<Brejost:> <in laktacija:>
<{MM/YYYY}>
<{Faks}>
<Adjuvant
:>
<Pomožna(pomožne) snov(i):>
<Store and transport refrigerated.>*
<Shranjujte in prevažajte v hladilniku.>*
<Excipient
:>
<Dodatek(dodatki):>
<Veterinary medicinal product subject to prescription.>
{(Izmišljeno) ime zdravila za uporabo v veterinarski medicini <jakost> farmacevtska oblika <ciljne živalske vrste>}
In that case the doctor will monitor your heart function.
V takšnem primeru vam bo zdravnik spremljal delovanje srca.
Interactions are likely to be similar to the adult population.
Medsebojna delovanja so verjetno podobna kot pri odraslih.
Clinical data from a longer waiting period are not available.
Klinični podatki o daljšem času čakanja niso na voljo.
This is more likely when certain medicines have been taken at the same time.
Za to je več možnosti, če sočasno jemljete določena zdravila.
The product information may be subsequently updated by the Member State competent authorities, in liaison with the Reference Member State, as appropriate, in accordance with the procedures laid down in Chapter 4 of Title III of Directive 2001/83/EC.
Informacije o zdravilu lahko v nadaljevanju dopolnijo pristojni organi držav članic v povezavi z referenčno državo članico, če je to primerno, v skladu s postopki, določenimi v poglavju 4 naslova III Direktive 2001/83/ES.
These effects may be life threatening.
Ti učinki so lahko smrtno nevarni.
The maximum dose is 60 g.
Največji odmerek je 60 g.
• Other local anaesthetics.
• druge lokalne anestetike,
Where to put the cream, how much to use and how long to leave it on for will depend on what it is needed for.
Kam boste nanesli kremo, koliko je boste uporabili in koliko časa jo boste pustili naneseno, je odvisno od tega, zakaj jo potrebujete.
This medicinal product is authorised in the Member States of the EEA under the following names: Austria
To zdravilo je odobreno v državah članicah EGP pod naslednjimi imeni:
Specific interaction studies in children have not been performed.
Specifičnih študij medsebojnega delovanja zdravil pri otrocih niso izvajali.
When you apply the cream, it is very important to exactly follow the instructions below:
Ko nanašate kremo, je zelo pomembno, da natančno upoštevate spodnja navodila: 1.
This Summary of Product Characteristics, labelling and package leaflet is the outcome of the referral procedure to which this Commission decision relates.
Ta Povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo so rezultat napotitvenega postopka, na katerega se nanaša ta odločba Komisije.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION <Date of first authorisation: {DD month YYYY}> <Date of latest renewal: {DD month YYYY}>
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM <Datum prve odobritve: {DD. mesec LLLL}> <Datum zadnjega podaljšanja: {DD. mesec LLLL}>
The usual dose for adults and adolescents over 12 years is 2 g (grams).
Običajen odmerek za odrasle in mladostnike, starejše od 12 let, je 2 g (grama).
EMLA Cream is indicated for:
Zdravilo EMLA krema je indicirano za:
Pharmacotherapeutic group: anesthetics, local; amides; ATC code: N01B B20
Farmakoterapevtska skupina: lokalni anestetiki, amidi; oznaka ATC: N01B B20 Mehanizem delovanja
No specific disturbances to the reproductive process have so far been reported, e.g. an increased incidence of malformations or other directly or indirectly harmful effects on the foetus.
Do zdaj niso poročali o specifičnih motnjah reproduktivnega procesa, npr. o povečani pogostnosti malformacij ali o drugih posrednih in neposrednih škodljivih učinkih na plod.
These are normal reactions to the cream and the anaesthetics and will disappear in a short while without any measures being needed.
To so normalne reakcije na kremo in anestetik, izginile bodo hitro in brez posebnega ukrepanja.
This leaflet was last revised in <{MM/YYYY}> <{month YYYY}>.
Navodilo je bilo nazadnje revidirano dne <{MM/LLLL}> <{mesec LLLL}>.
4) Application for > 1hour has not been documented.
4) Nanosi, ki so trajali več kot 1 uro, niso bili dokumentirani.
EMLA can be used during breastfeeding if clinically needed.
Zdravilo EMLA se lahko uporablja med obdobjem dojenja, če je klinično potrebno.
6 - 8 years
6 - 8 let
If this happens, the skin becomes bluish-grey due to a lack of oxygen.
Če pride do tega, se koža zaradi pomanjkanja kisika obarva modrikasto sivo.
It is put on the skin before certain medical procedures.
Na kožo ga nanesemo pred določenimi zdravstvenimi posegi.
This is because EMLA can affect the way some medicines work and some medicines can have an effect on EMLA.
Zdravilo EMLA namreč lahko vpliva na delovanje nekaterih drugih zdravil in nekatera zdravila lahko vplivajo na zdravilo EMLA.
Tell your doctor about anything else that makes you feel unwell while you are using EMLA.
Zdravniku povejte tudi za karkoli drugega, kar vam povzroča slabo počutje v času uporabe zdravila EMLA.
Remove the plastic backing.
Odstranite plastični hrbtni del.
This helps to stop pain on the skin; however you may still have the feelings of pressure and touch.
S tem preprečimo, da bi bolnik čutil bolečine na koži, še vedno pa lahko čuti pritisk in dotik.
This is done for 30 to 60 minutes before the ulcer is to be cleansed.
To je treba narediti od 30 do 60 minut pred čiščenjem razjede.
In particular, tell your doctor or pharmacist if you or your child have recently used or been given any of the following medicines:
Še zlasti morate zdravniku ali farmacevtu povedati, če ste vi ali vaš otrok pred nedavnim jemali ali prejemali katero od naslednjih zdravil:
Remove the cream with cotton gauze and start cleansing without delay.
Kremo odstranite z bombažno gazo in nato takoj začnite čistiti razjedo.
For further guidance on the appropriate use of the product in such procedures, please refer to Method of administration.
Za dodatna navodila glede ustrezne uporabe zdravila pri takšnih posegih glejte poglavje Način uporabe.
The medical procedure should then start straight away.
Po tem času je treba takoj začeti z izvajanjem zdravstvenega posega.
The cream is put on under a dressing for 2 to 5 hours.
Kremo je treba nanesti pod folijo za 2 do 5 ur.
Adults and Adolescents It can also be used:
Odrasli in mladostniki Zdravilo lahko uporabljamo tudi za:
This includes medicines that you buy without a prescription and herbal medicines.
To velja tudi za zdravila, ki ste jih dobili brez recepta, in za zdravila rastlinskega izvora.
It is reasonable to assume that lidocaine and prilocaine have been used in a large number of pregnant women and women of childbearing age.
Utemeljeno je mogoče domnevati, da je lidokain in prilokain uporabljalo že veliko nosečnic in žensk v rodni dobi.
This ocular reaction may have been influenced by the high pH of the formulation of the emulsion (approximately 9), but is probably also partly a result of the irritative potential of the local anaesthetics themselves.
Na očesno reakcijo je morda vplivala visoka vrednost pH emulzije (približno 9), verjetno pa je taka reakcija deloma tudi posledica dražeče narave samih lokalnih anestetikov.
Elderly No dose reduction is necessary in elderly patients (see sections 5.1 and 5.2).
Pri starejših bolnikih zmanjševanje odmerkov ni potrebno (glejte poglavji 5.1 in 5.2).
Table 2 Paediatric patients 0-11 years of age
Preglednica 2 Pediatrični bolniki v starosti 0-11 let Starostna skupina
With large doses of EMLA, consideration should be given to the risk of additional systemic toxicity in patients receiving other local anaesthetics or medicinal products structurally related to local anaesthetics, since the toxic effects are additive.
Pri uporabi velikih odmerkov zdravila EMLA je treba upoštevati tveganje za dodatno sistemsko toksično delovanje pri bolnikih, ki prejemajo še druge lokalne anestetike ali zdravila, ki so strukturno podobna lokalnim anestetikom, ker so toksični učinki teh zdravil aditivni.
Tell your doctor or pharmacist if you are using / taking, have recently used / taken or might use / take any other medicines.
Obvestite zdravnika ali farmacevta, če jemljete/uporabljate, ste pred kratkim jemali/uporabljali ali pa boste morda začeli jemati/uporabljati katero koli drugo zdravilo.
Since the rate of absorption from intact skin is slow, a patient showing signs of toxicity should be kept under observation for several hours following emergency treatment.
Ker je absorpcija z nepoškodovane kože počasna, je treba bolnike z znaki toksičnega delovanja zdravila opazovati še več ur po nujnem zdravljenju.
In patients with atopic dermatitis, a similar but shorter vascular reaction is seen, with erythema occurring after 30-60 minutes, indicating more rapid absorption through the skin (see section 4.4).
Pri bolnikih z atopijskim dermatitisom je mogoče opaziti podobno, a kratkotrajnejšo žilno reakcijo, pri kateri se rdečina pojavi po 30-60 minutah, kar kaže na hitrejšo absorpcijo skozi kožo (glejte poglavje 4.4).
They both stabilize neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby producing local anaesthesia.
Oba stabilizirata membrane nevronov z zaviranjem pretoka ionov, ki je potreben za nastanek in prevajanje dražljajev, in tako povzročita lokalno anestezijo.
What you need to know before you use EMLA Do not use EMLA
Kaj morate vedeti, preden boste uporabili zdravilo EMLA Ne uporabljajte zdravila EMLA
Table 1 Adults and adolescents 12 years of age and above Indication/Procedure
Preglednica 1 Odrasli in mladostniki, stari 12 let ali več Indikacija/poseg
if you are allergic to lidocaine or prilocaine, other similar local anaesthetics or any of the other ingredients of this medicine (listed in section 6).
če ste alergični na lidokain ali prilokain, druge podobne lokalne anestetike ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
if you or your child have an itchy skin condition called ‘atopic dermatitis', a shorter application time may be sufficient.
če imate vi ali ima vaš otrok srbečo kožno bolezen, imenovano "atopijski dermatitis"; v tem primeru lahko zadošča krajši čas nanosa zdravila.